130 likes | 217 Views
Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s P rogrammes at the University of Pécs and at the University of Debrecen Identification number : TÁMOP-4.1.2-08/1/A-2009-0011.
E N D
Manifestation of Novel Social Challenges of the European Unionin the Teaching Material ofMedical Biotechnology Master’s Programmesat theUniversity of Pécs and at the University of Debrecen Identificationnumber: TÁMOP-4.1.2-08/1/A-2009-0011
Manifestation of Novel Social Challenges of the European Unionin the Teaching Material ofMedical Biotechnology Master’s Programmesat theUniversity of Pécs and at the University of Debrecen Identification number: TÁMOP-4.1.2-08/1/A-2009-0011 Dr. Judit Pongrácz Threedimensionaltissuecultures and tissueengineering – Lecture 27 Ethicalissues
No ethicalissuesraised • Autologouscells • No life threateningconditions
More ethicalquestions • Advanced human tissueengineeringtherapiesmayalso be usedforlife-threateningconditions • Embryonicstemcells • Xenogeneiccells
Regulationin Europe • Best regulated at European level • European framework laws • Directives adopted by the European Commission and the European Parliament must be incorporated in national law
The most relevantdocuments • Charter of FundamentalRightsofthe EU • ConventiononBiomedicine
Rulingin 2011 • A singlecellfrom an embryocan be consideredas a human being.
USA • Embryonicstemcellscannot be used • Onlyestablishedcelllinescan be usedinresearch • Adultstemcellscan be appliedinresearch
Manifestation of Novel Social Challenges of the European Unionin the Teaching Material ofMedical Biotechnology Master’s Programmesat theUniversity of Pécs and at the University of Debrecen Identification number: TÁMOP-4.1.2-08/1/A-2009-0011 Dr. Judit Pongrácz Threedimensionaltissuecultures and tissueengineering – Lecture 28 Economicsignificance
Biotechnology Medical Pharmaceutical Agricultural, etc
Significanceinthe US In2001, 3,300 scientists and supportstaffworkedintissueengineeringalone Over 70 start-upcompanies Investment of 3.5 billionUS dollars
Significanceinthe EU Fastgrowing STILL No venturecapitalin Europe
Big Pharma Refocusingtocellbasedtherapies Noveltherapeuticapproachesjustintreatment of diabeticpatientsalone